Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials
| Autor: | Paul S. Tofts, Michael V. Knopp, R Rathbone, John C. Waterton, Michael R. Horsman, Dominick J.O. McIntyre, W Vennart, A. Jackson, R. J. Maxwell, Gordon C Jayson, John R. Griffiths, Stephen R. Williams, Martin O. Leach, Anwar R. Padhani, Patricia M Price, Jeffrey L. Evelhoch, G. M. Tozer, G. J. S. Rustin, Ian Judson, Kevin M. Brindle, Paul Workman |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
medicine.medical_specialty
Clinical Trials as Topic medicine.diagnostic_test Neovascularization Pathologic business.industry Advisory committee Reproducibility of Results Magnetic resonance imaging Angiogenesis Inhibitors General Medicine Clinical trial Drug Design Neoplasms medicine Humans Radiology Nuclear Medicine and imaging Medical physics Stage (cooking) Nuclear medicine business Magnetic Resonance Angiography |
| Zdroj: | The British journal of radiology. |
| ISSN: | 0007-1285 |
| Popis: | MRI is increasingly being used to evaluate antiangio-genic and antivascular agents in early stage clinical trials.The measurement and analysis methodology required forrobust application of MRI to such trials has beenconsidered by specialist panels in a workshop, resultingin recommendations for the design and analysis of trials,and identification of areas requiring further development.The following document is the text of the poster presentedbyCancerResearchUKPharmacodynamic/PharmacokineticTechnologies Advisory Committee (PTAC) on the use ofMRI for the evaluation of antiangiogenic and antivascularcancer drugs presented at the American Association forCancer Research, Washington (2003) and at the Inter-national Society of Magnetic Resonance in Medicine, 11thScientific meeting, Toronto, 2003 [1, 2]. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|